Transcranial sonography in Parkinson's disease

Zhurnal Nevrologii i Psihiatrii imeni S.S. Korsakova

Volumn 111, Issue 1, 2011, Pages 49-55

  Fedotova, E Yu ^a   Chechetkin, A O ^a   Shadrina, M I ^a   Slominsky, P A ^a   Ivanova Smolenskaya, I A ^a   Illarioshkin, S N ^a  

^a NONE

Author keywords

Atypical parkinsonism; Differential diagnosis; Essential tremor; Parkinson's disease; Transcranial sonography

Indexed keywords

ARTICLE; CONTROLLED STUDY; DISCRIMINANT ANALYSIS; DOPPLER ECHOGRAPHY; HUMAN; IDIOPATHIC DISEASE; MAJOR CLINICAL STUDY; PARKINSON DISEASE; PARKINSONISM; SIGNAL DETECTION; SUBSTANTIA NIGRA; ADULT; AGED; DIFFERENTIAL DIAGNOSIS; EARLY DIAGNOSIS; ECHOGRAPHY; EVALUATION; FEMALE; MALE; MIDDLE AGED;

ADULT; AGED; DIAGNOSIS, DIFFERENTIAL; EARLY DIAGNOSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; SUBSTANTIA NIGRA; ULTRASONOGRAPHY, DOPPLER, TRANSCRANIAL;

EID: 79953309337     PISSN: 19977298     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Russian source
2. Russian source
3. Russian source
4. Becker G., Seufert J., Bogdahn U. et al. Degeneration of substantia nigra in chronic Parkinson's disease visualized by transcranial color-coded realtime sonography. Neurology 1995; 45: 182-184.
5. Behnke S., Berg D., Becker G. Does ultrasound disclose a vulnerability factor for Parkinson's disease? J Neurol 2003; 250: Suppl 1: 24-27.
6. Behnke S., Berg D., Naumann M. et al. Differentiation of Parkinson's disease and atypical parkinsonian syndromes by transcranial ultrasound. J Neurol Neurosurg Psychiat 2005; 76: 423-425.
7. Berg D. Disturbance of iron metabolism as a contributing factor to SN hyperechogenicity in Parkinson's disease: Implications for idiopathic and monogenetic forms. Neurochem Res 2007; 32: 1646-1654.
8. Berg D. Transcranial ultrasound as a risk marker for Parkinson's disease. Mov Disord 2009; 24: S2: 677-683.
9. Berg D., Behnke S., Walter U. Application of transcranial Sonography in extrapyramidal disorder: Updated Recommendation. Ultraschall Med 2006; 27: 12-19.
10. Berg D., Godau J., Walter U. Transcranial sonography in movement disorders. Lancet Neurol 2008; 7: 1044-1055.
11. Berg D., Hochstrasser H. Iron Metabolism in parkinsonian syndromes. Mov Disord 2006; 21: 9: 1299-1310.
12. Berg D., Jabs B., Merschdorf U. et al. Echogenicity of substantia nigra determined by transcranial ultrasound correlates with severity of parkinsonian symptoms induced by neuroleptic therapy. Biol Psychiat 2001; 50: 463-467.
13. Berg D., Roggendorf W., Schroder U. et al. Echogenicity of the substantia nigra: Association with increased iron content and marker for susceptibility to nigrostriatal injury. Arch Neurol 2002; 59: 999-1005.
14. Berg D., Siefker C., Becker G. Echogenicity of the substantia nigra in Parkinson's disease and its relation to clinical findings. J Neurol 2001; 248: 684-689.
15. Boesveldt S., Verbaan D., Knol D. et al. A comparative study of odor identification and odor discrimination deficits in Parkinson's disease. Mov Disord 2008; 23: 14: 1984-1990.
16. Boeve B.F., Silber M.H., Saper C.B. et al. Pathophysiology of REM sleep behaviour disorder and relevance to neurodegenerative disease. Brain 2007; 130: 2770-2788.
17. Dickson D.W., Braak H., Duda J.E. et al. Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria. Lancet Neurol 2009; 8: 1150-1157.
18. Doepp F., Plotkin M., Siegel L. et al. Brain parenchyma sonography and 123I-FP-CIT SPECT in Parkinson's disease and essential tremor. Mov Disord 2008; 23: 405-410.
19. Fearnley J.M., Lees A.J. Ageing and Parkinson's disease: Substantia nigra regional selectivity. Brain 1991; 114: 2283-2301.
20. Gaenslen A., Unmuth B., Godau J. et al. The specificity and sensitivity of transcranial ultrasound in the differential diagnosis of Parkinson's disease: a prospective blinded study. Lancet Neurol 2008; 7: 417-424.
21. Hagenah J.M., Konig I.R., Becker B. et al. Substantia nigra hyperechogenicity correlates with clinical status and number of Parkin mutated alleles. J Neurol 2007; 254: 1407-1413.
22. Harbo H.F., Finsterer J., Baets J. et al. EFNS guidelines on the molecular diagnosis of neurogenetic disorders: general issues, Huntington's disease, Parkinson's disease and dystonias. Eur J Neurol 2009; 16: 777-785.
23. Jankovic J. Parkinson's disease: clinical features and diagnosis. J Neurol Neurosurg Psychiat 2008; 79: 368-376.
24. Jellinger K., Paulus W., Grundke-Iqbal I. et al. Brain iron and ferritin in Parkinson's and Alzheimer's disease. J Neural Transm 1990; Sect 2: 327-340.
25. Klein C., Lohmann-Hedrich K., Rogaeva E. et al. Deciphering the role of heterozygous mutations in genes associated with parkinsonism. Lancet Neurol 2007; 6: 652-662.
26. Lesage S., Brice A. Parkinson's disease: from monogenic forms to genetic susceptibility factors. Hum Mol Genet 2009; 18: R48-59.
27. Mijajlovic M., Dragasevic N., Stefanova E. et al. Transcranial sonography in spinocerebellar ataxia type 2. J Neurol 2008; 255: 1164-1167.
28. Pavese N., Brooks D.J. Imaging neurodegeneration in Parkinson's disease. Biochim Biophys Acta 2008; doi:10.1016/j.bbadis.2008.10.003.
29. Schweitzer K., Bruessel T., Leitner P. et al. Transcranial ultrasound in different monogenetic subtypes of Parkinson's disease. J Neurol 2007; 254: 613-616.
30. Shadrina M.I., Semenova E.V., Slominsky P.A. et al. Effective quantitative real-time polymerase chain reaction analysis of the parkin gene (PARK2) exon 1-12 dosage. BMC Med Genet 2007; 8: 6.
31. Spiegel J., Hellwig D., Moellers M.-O. et al. Transcranial sonography and [123I]FP-CIT SPECT disclose complementary aspects of Parkinson's disease. Brain 2006; 129: 1188-1193.
32. Stefanova N., Bucke P., Duerr S. et al. Multiple system atrophy: an update. Lancet Neurol 2009; 8: 1172-1178.
33. Stockner H., Sojer M., Seppi K. et al. Midbrain sonography in patients with essential tremor. Mov Disord 2007; 22: 414-417.
34. Stoffers D., Bosboom J.L.W., Deijen J.B. et al. Slowing of oscillatory brain activity is a stable characteristic of Parkinson's disease without dementia. Brain 2007; 130: 1847-1860.
35. Tolosa E., Wenning G., Poewe W. The diagnosis of Parkinson's disease. Lancet Neurol 2006; 5: 75-86.
36. Tsai C.-F., Wu R.-M., Huang Y.-W. et al. Transcranial color-coded sonography helps differentiation between idiopathic Parkinson's disease and vascular parkinsonism. J Neurol 2007; 254: 501-507.
37. Vlaar A.M., de Nijs T., van Kroonenburgh M. JPG. et al. The predictive value of transcranial duplex sonography for the clinical diagnosis in undiagnosed parkinsonian syndromes: comparison with SPECT scans. BMC Neurology 2008; 8: 42.
38. Walter U., Behnke S., Eyding J. et al. Transcranial brain parenchyma sonography in movement Disorders: state of the art. Ultrasound Med 2007; 33: 15-25.
39. Walter U., Dressler D., Lindemann C. et al. Transcranial sonography findings in welding-related parkinsonism in comparison to Parkinson's disease. Mov Disord 2008; 23: 1: 141-145.
40. Walter U., Dressler D., Probst T. et al. Transcranial brain sonography findings in discrimination between parkinsonism and idiopathic Parkinson's disease. Arch Neurol 2007; 64: 11: 1635-1640.
41. Walter U., Dressler D., Wolters A. et al. Sonographic discrimination of corticobasal degeneration vs progressive supranuclear palsy. Neurology 2004; 63: 504-509.
42. Walter U., Hoeppner J., Prudente-Morrissey L. et al. Parkinson's disease-like midbrain sonography abnormalities are frequent in depressive disorders. Brain 2007; 130: 1799-1807.
43. Walter U., Niehaus L., Probst T. et al. Brain parenchyma sonography discriminates Parkinson's disease and atypical parkinsonian syndromes. Neurology 2003; 60: 74-77.
44. Williams D.R., Lees A.J. Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges. Lancet Neurol 2009; 8: 270-279.